HAVCR2 and neoplasm: Finally, dual immunomodulators target two immunomodulating proteins resulting in the blockade of inhibitory checkpoint pathways, counteracting tumours’ immunosuppressive mechanisms.28 The latter category comprises the two PD-1/TIM3 bispecific Abs currently under investigation in phase I trials (table 1).